Lewin C S, Watt B, Paton R, Amyes S G
Bacteriology Department, University Medical School, Edinburgh, U.K.
FEMS Microbiol Lett. 1990 Jul;58(2):141-3. doi: 10.1111/j.1574-6968.1990.tb13967.x.
Zidovudine-resistant Escherichia coli were isolated from faecal samples from 6 out of 11 AIDS patients receiving zidovudine. Resistance appeared to be due to the loss of thymidine kinase activity which is required for the phosphorylation of zidovudine to its active form. No zidovudine resistant enterobacteria were isolated from 30 control faecal samples. Hence, clinically, there appeared to be a high correlation between the development of zidovudine-resistance in E. coli and exposure to zidovudine (chi 2: 11.77, P less than 0.001). However the development of zidovudine resistance does not appear to be associated with cross-resistance to other antimicrobial agents as the zidovudine-resistant E. coli did not display a high degree of resistance to other antibacterials.
从11名接受齐多夫定治疗的艾滋病患者的粪便样本中，分离出了6株对齐多夫定耐药的大肠杆菌。耐药性似乎是由于胸苷激酶活性丧失所致，而胸苷激酶是将齐多夫定磷酸化为其活性形式所必需的。从30份对照粪便样本中未分离出对齐多夫定耐药的肠杆菌。因此，临床上，大肠杆菌中齐多夫定耐药性的产生与接触齐多夫定之间似乎存在高度相关性（卡方值：11.77，P<0.001）。然而，齐多夫定耐药性的产生似乎与对其他抗菌药物的交叉耐药性无关，因为对齐多夫定耐药的大肠杆菌对其他抗菌药物并未表现出高度耐药性。
